Sugi Predict

Sugi Predict / Compounds / SCHEMBL3282371

SCHEMBL3282371

SCHEMBL3282371

Cn1cc([N+](=O)[O-])nc1Br

nearest known ligand 0.45

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.44
▸ SOS1 Q07889 1/20 0.36
▸ GAA P10253 3/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ MITF O75030 1/20 0.36
▸ PKM P14618 1/20 0.35
▸ MAPT P10636 3/20 0.34
▸ LMNA P02545 3/20 0.34
▸ KMT2A Q03164 3/20 0.34
▸ HTT P42858 1/20 0.34
▸ BLM P54132 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL63286 0.78 ALDH1A1 (0.59) ALDH1A1SOS1GAAKDM4EMITF
SCHEMBL5353581 0.78 MITF (0.46) ALDH1A1SOS1GAAKDM4EMITF
SCHEMBL19674728 0.76 ALDH1A1 (0.44) ALDH1A1SOS1GAAKDM4EMITF
SCHEMBL27890859 0.76 ALDH1A1 (0.41) ALDH1A1SOS1MITFPKMMAPT
SCHEMBL10108152 0.76 ALDH1A1 (0.45) ALDH1A1SOS1GAAKDM4EMITF
SCHEMBL869168 0.76 ALDH1A1 (0.45) ALDH1A1SOS1GAAKDM4EMITF
SCHEMBL25791997 0.76 ALDH1A1 (0.41) ALDH1A1SOS1GAAKDM4EMITF
SCHEMBL27849202 0.74 ALDH1A1 (0.40) ALDH1A1SOS1GAAKDM4EMITF
SCHEMBL5331712 0.73 ALDH1A1 (0.42) ALDH1A1SOS1GAAKDM4EMITF
SCHEMBL18786131 0.73 ALDH1A1 (0.50) ALDH1A1SOS1GAAKDM4EMITF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118852153-A NLRP3 inflammation corpuscle inhibitor and application thereof 药捷安康(南京)科技股份有限公司 2024-10-29 — — CN disclosed
WO-2024175804-A1 NUCLEAR TRANSPORT MODULATORS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2024-08-29 — — WO disclosed
US-12043623-B2 Purinones as ubiquitin-specific protease 1 inhibitors FORMA THERAPEUTICS, INC. (US) 2024-07-23 — — US disclosed
US-12043623-B2 Purinones as ubiquitin-specific protease 1 inhibitors FORMA THERAPEUTICS, INC. (US) 2024-07-23 — — US disclosed
CN-117801276-B Polyimide film and preparation method thereof 中国科学院长春应用化学研究所 2024-05-17 — — CN disclosed
CN-117801276-A Polyimide film and preparation method thereof 中国科学院长春应用化学研究所 2024-04-02 — — CN disclosed
US-20220281869-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS FORMA THERAPEUTICS, INC. 2022-09-08 — — US disclosed
CN-114702495-A Purinones as ubiquitin-specific protease 1 inhibitors 福马治疗有限公司 2022-07-05 — — CN disclosed
CN-108473495-B Purinones as ubiquitin-specific protease 1 inhibitors 福马治疗有限公司 2022-04-12 — — CN disclosed
US-11161848-B2 Purinones as ubiquitin-specific protease 1 inhibitors FORMA THERAPEUTICS, INC. (US) 2021-11-02 — — US disclosed
US-20180339986-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS FORMA THERAPEUTICS, INC. 2018-11-29 — — US disclosed
EP-3377493-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS Forma Therapeutics, Inc. (US) 2018-09-26 — — EP disclosed
US-20170145012-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS FORMA THERAPEUTICS, INC. 2017-05-25 — — US disclosed
US-20170145012-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS FORMA THERAPEUTICS, INC. 2017-05-25 — — US disclosed
US-20170145012-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS FORMA THERAPEUTICS, INC. 2017-05-25 — — US disclosed
US-7709503-B2 Pyrrol derivatives with antibacterial activity ASTRAZENECA AB (SE) 2010-05-04 — — US disclosed
US-20090082575-A1 PROCESS FOR PRODUCTION OF 2-CHLORO-4-NITROIMIDAZOLE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-03-26 — — US disclosed
US-20090082575-A1 PROCESS FOR PRODUCTION OF 2-CHLORO-4-NITROIMIDAZOLE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-03-26 — — US disclosed
EP-1664025-B1 PYRROL DERIVATIVES WITH ANTIBACTERIAL ACTIVITY ASTRAZENECA AB (SE) 2007-09-19 — — EP disclosed
US-20060223801-A1 Pyrrol derivatives with antibacterial activity ASTRAZENECA AB (SE) 2006-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082575-A1 PROCESS FOR PRODUCTION OF 2-CHLORO-4-NITROIMIDAZOLE COX4I1, MT-ND4, MT-ND4L ALDH1A1 430/4885SOS1 4042/4885GAA 3140/4885
US-20060223801-A1 Pyrrol derivatives with antibacterial activity PEF1, PEPD, PELP1 ALDH1A1 976/4885SOS1 2808/4885GAA 561/4885
US-11161848-B2 Purinones as ubiquitin-specific protease 1 inhibitors USP1, UBA1, UBXN1 ALDH1A1 633/4885SOS1 2063/4885GAA 1605/4885
US-20180339986-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS USP1, UBA1, UBXN1 ALDH1A1 633/4885SOS1 2063/4885GAA 1605/4885
US-20170145012-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS USP1, UBA1, UBXN1 ALDH1A1 633/4885SOS1 2063/4885GAA 1605/4885
US-20220281869-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS USP1, UBA1, UBXN1 ALDH1A1 633/4885SOS1 2063/4885GAA 1605/4885
US-12043623-B2 Purinones as ubiquitin-specific protease 1 inhibitors USP1, UBA1, UBXN1 ALDH1A1 633/4885SOS1 2063/4885GAA 1605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.